Track topics on Twitter Track topics that are important to you
PEABODY, Mass., June 4, 2015 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced results for its third quarter ended April 30, 2015.
Highlights during the third quarter (comparisons are against Q3 of fiscal 2014) included:
Revenue for the third quarter of fiscal 2015 was $133.6 million, an increase of 8% compared with revenue of $124.0 million in the third quarter of fiscal 2014. GAAP net income for the third quarter of fiscal 2015 was $9.1 million, or $0.72 per diluted share, compared with net income of $7.8 million, or $0.62 per diluted share, in the third quarter of fiscal 2014. Non-GAAP net income for the third quarter was $13.5 million, or $1.07 per diluted share, compared with $11.8 million, or $0.94 per diluted share, in the prior year's third quarter. Included in both GAAP and non-GAAP net income for the third quarter of fiscal 2015 is $3.0 million, or $0.24 per diluted share, of discrete tax benefits.
For the first nine months of fiscal 2015, revenue totaled $385.8 million, consistent with the same period in the prior year. Year-to-date GAAP net income was $22.6 million, or $1.79 per diluted share, compared with $23.3 million, or $1.84 per diluted share, from the same period last year.
Included in our GAAP net income last fiscal year were discrete tax benefits of $8.8 million, or $0.69 per diluted share. Year-to-date non-GAAP net income was $35.0 million, or $2.77 per diluted share, compared with $27.5 million, or $2.17 per diluted share, in the same period last year. Included in both GAAP and non-GAAP net income for the first nine months of fiscal 2015 is $3.0 million, or $0.24 per diluted share, of discrete tax benefits.
Jim Green, president and CEO, commented, "Our operating performance for the third quarter was inline with our expectations. Overall business revenue grew 10% on a constant currency basis with solid Ultrasound performance in North America and Europe. As expected, our Security business saw very strong growth and our Medical Imaging business remained stable."
Green continued, "For the fourth quarter we see strong revenue growth, driven by double-digit growth in Ultrasound and Security. We expect overall fiscal year revenue to grow 3-4%, with mid-single-digit growth on a constant currency basis and non-GAAP operating margins improving 1-2 points."
Revenue from our Medical Imaging segment was $71.9 million for the third quarter of fiscal 2015, consistent with revenue of $71.6 million in the same period of fiscal 2014. Medical Imaging revenues remain flat on a quarterly basis driven by CT and mammography, offset by MRI. On a year-to-date basis, Medical Imaging revenue was $211.8 million, consistent with the prior year.
Our Ultrasound segment revenue was $38.6 million for the third quarter of fiscal 2015, 3% growth over the $37.3 million in the same period of fiscal 2014. On a constant currency basis, the growth in Ultrasound was 10% for the quarter due to strong sales in North America and Europe. Year-to-date, Ultrasound revenue was $118.8 million, up 6% from the prior year, or 10% in constant currency.
Security and Detection segment revenue was $23.1 million for the third quarter of fiscal 2015, up 53% from revenue of $15.1 million in the same period of fiscal 2014, due to the timing of medium-speed and high-speed system shipments, as a large portion of our stated backlog had been scheduled to ship in the back half of the fiscal year. Year-to-date, Security and Detection revenue was $55.2 million, up 6% from the prior year.
Quarterly Cash Dividend
On June 1, 2015, Analogic's Board of Directors declared a $0.10 cash dividend for each common share for its third fiscal quarter ended April 30, 2015. The cash dividend will be payable on June 29, 2015 to shareholders of record on June 15, 2015.
Use of Non-GAAP Financial Measures
This document includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.
Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. An explanation and a reconciliation of our non-GAAP measures are provided at the end of this press release.
Any statements about future expectations, plans, and prospects for the Company, including statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to product development and commercialization, limited demand for the Company's products, limited number of customers, risks associated with competition, uncertainties associated with regulatory agency approvals, competitive pricing pressures, downturns in the economy, the risk of potential intellectual property litigation, acquisition related risks, and other factors discussed in our most recent quarterly and annual reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this document. While the Company anticipates that subsequent events and developments will cause the Company's views to change, the Company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any later date.
Analogic will conduct an investor conference call on Thursday, June 4, 2015 at 5:00 p.m. (ET) to discuss results for the third quarter ended April 30, 2015. To participate in the conference call, dial 1-866-823-6992, or 1-334-323-7225 for international callers, approximately ten minutes before the conference is scheduled to begin. Inform the operator that you wish to join the Analogic conference call, passcode 42748. You will then be asked for your name, organization, and telephone number, and be connected to the conference. The earnings release and, just prior to the call, presentation materials related to the quarterly financial information will be posted on the Company's investor relations website at http://investor.analogic.com.
The call will also be available via webcast in listen-only mode. To listen to the webcast, visit http://investor.analogic.com approximately five to ten minutes before the conference is scheduled to begin. A telephone digital replay will be available approximately two hours after the call is completed through midnight (ET), Sunday, July 5, 2015. To access the digital replay, dial 1-877-919-4059, or 1-334-323-0140 for international callers. The passcode is 45721223.
The replay of the conference call webcast will be archived at http://investor.analogic.com approximately three hours after the call is completed and will be available through midnight (ET), Sunday, July 5, 2015.
Analogic (Nasdaq:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com.
Analogic and the globe logo are registered trademarks of Analogic Corporation.
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three Months Ended||Nine Months Ended|
|(In thousands, except per share data)||April 30, 2015||April 30, 2014||April 30, 2015||April 30, 2014|
|Total net revenue||133,559||124,032||385,820||375,551|
|Cost of sales:|
|Total cost of sales||77,606||70,678||220,375||218,177|
|Research and product development||17,156||16,915||50,950||55,795|
|Selling and marketing||15,928||14,338||47,283||43,603|
|General and administrative||15,339||12,764||42,634||40,624|
|Total operating expenses||48,316||43,937||140,550||140,238|
|Income from operations||7,637||9,417||24,895||17,136|
|Total other income, net||201||882||150||104|
|Income before income taxes||7,838||10,299||25,045||17,240|
|(Benefit from) provision for income taxes||(1,286)||2,509||2,437||(6,089)|
|Net income per share|
|Dividends declared and paid per share||$0.10||$0.10||$0.30||$0.30|
|Weighted-average shares outstanding:|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|Assets:||April 30, 2015||July 31, 2014|
|Cash and cash equivalents||$119,835||$114,540|
|Accounts receivable, net||101,994||106,436|
|Other current assets||30,610||28,021|
|Total current assets||397,690||373,774|
|Property, plant, and equipment, net||107,746||114,165|
|Intangible assets and goodwill, net||109,096||114,321|
|Other non-current assets||10,004||12,082|
|Liabilities and Stockholders' Equity:|
|Other current liabilities||11,487||13,807|
|Total current liabilities||83,072||84,513|
|Total Liabilities and Stockholders' Equity||$624,536||$614,342|
UNAUDITED SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP MEASURES
We provide non-GAAP income from operations, other income, net income, and diluted net income per share as supplemental measures to reported results regarding our operational performance. These financial measures exclude the impact of certain items and, therefore, have not been calculated in accordance with GAAP. The adjustments to these financial measures, and the basis for such adjustments, are outlined below:
Share-Based Compensation Expense
We incur expense related to share-based compensation included in the reported presentation of cost of sales, research and development, selling and marketing, and general and administrative expense. Although share-based compensation is an expense and viewed as a form of compensation, these expenses vary in amount from period to period. In addition, fluctuations in market price and volatility of our shares, risk-free interest rates, the expected term and forfeiture rates of the awards impact the expense period to period. A portion of our equity compensation is performance-based, which drives volatility in expense as estimated performance-based metrics are updated for actual and forecasted results. Our management team believes that exclusion of these expenses allows comparisons of operating results that are consistent between periods and allows comparisons of our operating results to those of other companies that disclose non-GAAP financial measures that exclude share-based compensation.
BK Medical Distributor Matter Inquiry-Related Costs
In fiscal year 2011, we identified transactions involving our Danish subsidiary, BK Medical, and certain of its foreign distributors, with respect to which we have raised questions concerning compliance with law and our business policies. We have concluded that the identified transactions have been properly accounted for in our reported consolidated financial statements in all material respects. During the three and nine months ended April 30, 2015 we incurred $0.3 million and $1.4 million of pre-tax inquiry-related costs, respectively. We incurred $0.4 million and $1.3 million of pre-tax inquiry-related costs during the three and nine months ended April 30, 2014, respectively.
Acquisition-related expenses relate to the amortization of intangibles and fair value adjustments associated with assets acquired and contingent liabilities from our business combinations. These expenses also include other transaction costs related to the acquisitions. The intangible assets are valued at the time of acquisition and are amortized over their estimated economic life. We believe the exclusion of these acquisition related expenses allow comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses. During the three and nine months ended April 30, 2015, we incurred $2.3 million and $6.8 million of pre-tax acquisition-related expenses, respectively. We incurred $2.1 million and $7.2 million of pre-tax acquisition-related costs during the three and nine months ended April 30, 2014, respectively.
During the fourth quarter of fiscal year 2014, we implemented our fiscal year 2014 restructuring plan (FY14 restructuring plan) to optimize our operations in Peabody, Massachusetts, which affected 48 employees. In May 2013, we announced our fiscal year 2013 restructuring plan (FY13 restructuring plan) primarily relating to severance and personnel related costs of 115 involuntarily terminated employees, as well as for facility exit costs associated with restructuring activities, including the consolidation of manufacturing and certain support activities currently conducted at the Ultrasonix facility in Vancouver, into operations at our existing facilities, closure of the Ultrasonix sales subsidiary in Paris, France, the transition costs associated with the planned closure of our Englewood, Colorado facility, as we consolidated certain ultrasound transducer manufacturing and development activities into our State College, Pennsylvania facility, and optimization of our operations in Montreal, Canada and Peabody Massachusetts. We continue to have adjustments on our FY14 restructuring plan through April 30, 2015, as we expect to complete restructuring activities in fiscal year 2015 for the FY 14 plan; we substantially completed restructuring activities in fiscal year 2014 for the FY13 plan. We incurred $(0.1) million and $(0.3) million of pre-tax restructuring costs during the three and nine months ended April 30, 2015.
For purposes of calculating non-GAAP net income and non-GAAP diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the non-GAAP adjustments described above as they have a significant impact on our income tax provision (benefit). In addition, from time-to-time, we recognize certain non-recurring tax adjustments.
During the nine months ended April 30, 2014, we excluded from our non-GAAP results $8.8 million in non-recurring tax benefits primarily associated with our Canadian operations. These benefits were excluded from our non-GAAP results as the significant benefit recorded in the second quarter of fiscal year 2014 was non-recurring and management believes not helpful in evaluating short-term and longer-term trends in our operations. No similar benefit or adjustment was recognized during the three and nine months ended April 30, 2015.
We exclude the above-described expenses, their related tax impact and other non-recurring tax benefits in evaluating short-term and long-term operating trends in our operations, and allocating resources to various initiatives and operational requirements. We believe that these non-GAAP financial adjustments are useful to investors because they allow investors to evaluate the effectiveness of the methodology and information used by management in its financial and operational decision-making.
These non-GAAP financial measures have not been prepared in accordance with GAAP, and should not be considered in isolation or as a substitute for financial information provided in accordance with GAAP. Further, these non-GAAP financial measures may not be computed in the same manner as similarly titled measures used by other companies. The following table reconciles the non-GAAP financial measures to their most directly comparable GAAP financial measures.
|NON-GAAP STATEMENTS OF OPERATIONS RECONCILIATION|
|(In thousands, except per share data)||Three Months Ended||Nine Months Ended|
|April 30, 2015||April 30, 2014||April 30, 2015||April 30, 2014|
|GAAP Income From Operations||$7,637||$9,417||$24,895||$17,136|
|Share-based compensation expense||3,393||2,888||8,408||8,727|
|Acquisition-related revenues and expenses||2,287||2,148||6,834||6,674|
|BK distributor matter inquiry related costs||258||417||1,404||1,328|
|Non-GAAP Income From Operations||$13,468||$14,790||$41,224||$34,081|
|Percentage of Total Net Revenue||10.1%||11.9%||10.7%||9.1%|
|GAAP Other Income, net||$201||$882||$150||$104|
|Acquisition related loss||--||--||--||484|
|Non-GAAP Other Income, net||$201||$882||$150||$588|
|Percentage of Total Net Revenue||0.2%||0.7%||0.0%||0.2%|
|GAAP Net Income||$9,124||$7,790||$22,608||$23,329|
|Share-based compensation expense||2,366||2,064||5,897||6,026|
|Acquisition related revenues, expenses and loss||1,924||1,772||5,765||5,888|
|BK distributor matter inquiry related costs||165||263||893||844|
|Non-GAAP Net Income||$13,511||$11,832||$34,962||$27,463|
|Percentage of Total Net Revenue||10.1%||9.5%||9.1%||7.3%|
|GAAP Diluted Net Income Per Share||$0.72||$0.62||$1.79||$1.84|
|Effect of non-GAAP adjustments||0.35||0.32||0.98||0.33|
|Non-GAAP Diluted Net Income Per Share||$1.07||$0.94||$2.77||$2.17|
CONTACT: Investor Contact: Mark Namaroff (978) 326-4058 firstname.lastname@example.orgNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...